Tags

Type your tag names separated by a space and hit enter

Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.
J Immunol Res. 2021; 2021:9945725.JI

Abstract

Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous genetic and molecular researches have confirmed the significant role of the complement system in the pathogenesis of AMD, leading to a deeper exploration of complement inhibitors in the treatment of AMD. To date, at least 14 different complement inhibitors have been or are being explored in AMD in almost 40 clinical trials. While most complement inhibitors fail to treat AMD successfully, two of them are effective in inhibiting the rate of GA progression in phase II clinical trials, and both of them successfully entered phase III trials. Furthermore, recently emerging complement gene therapy and combination therapy also offer new opportunities to treat AMD in the future. In this review, we aim to introduce genetic and molecular associations between the complement system and AMD, provide the updated progress in complement inhibitors in AMD on clinical trials, and discuss the challenges and prospects of complement therapeutic strategies in AMD.

Authors+Show Affiliations

Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Department of Ophthalmology, Beijing Moslem People's Hospital, Beijing, China.Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34368372

Citation

Qin, Shuqi, et al. "Complement Inhibitors in Age-Related Macular Degeneration: a Potential Therapeutic Option." Journal of Immunology Research, vol. 2021, 2021, p. 9945725.
Qin S, Dong N, Yang M, et al. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. J Immunol Res. 2021;2021:9945725.
Qin, S., Dong, N., Yang, M., Wang, J., Feng, X., & Wang, Y. (2021). Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. Journal of Immunology Research, 2021, 9945725. https://doi.org/10.1155/2021/9945725
Qin S, et al. Complement Inhibitors in Age-Related Macular Degeneration: a Potential Therapeutic Option. J Immunol Res. 2021;2021:9945725. PubMed PMID: 34368372.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. AU - Qin,Shuqi, AU - Dong,Ning, AU - Yang,Ming, AU - Wang,Jialin, AU - Feng,Xue, AU - Wang,Yanling, Y1 - 2021/07/29/ PY - 2021/03/15/received PY - 2021/07/07/revised PY - 2021/07/14/accepted PY - 2021/8/9/entrez PY - 2021/8/10/pubmed PY - 2021/8/10/medline SP - 9945725 EP - 9945725 JF - Journal of immunology research JO - J Immunol Res VL - 2021 N2 - Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous genetic and molecular researches have confirmed the significant role of the complement system in the pathogenesis of AMD, leading to a deeper exploration of complement inhibitors in the treatment of AMD. To date, at least 14 different complement inhibitors have been or are being explored in AMD in almost 40 clinical trials. While most complement inhibitors fail to treat AMD successfully, two of them are effective in inhibiting the rate of GA progression in phase II clinical trials, and both of them successfully entered phase III trials. Furthermore, recently emerging complement gene therapy and combination therapy also offer new opportunities to treat AMD in the future. In this review, we aim to introduce genetic and molecular associations between the complement system and AMD, provide the updated progress in complement inhibitors in AMD on clinical trials, and discuss the challenges and prospects of complement therapeutic strategies in AMD. SN - 2314-7156 UR - https://www.unboundmedicine.com/medline/citation/34368372/Complement_Inhibitors_in_Age_Related_Macular_Degeneration:_A_Potential_Therapeutic_Option_ L2 - https://doi.org/10.1155/2021/9945725 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.